Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Inlyta
Pharma
Merck, Eisai turn up the heat in kidney cancer with survival win
Plenty of combos are already vying for share in previously untreated kidney cancer, but that’s not stopping Merck and Eisai.
Carly Helfand
Feb 13, 2021 12:39pm
BMS, Exelixis' Opdivo-Cabometyx continues kidney cancer streak
Feb 9, 2021 10:49am
Opdivo, Cabometyx in FDA fast lane for kidney nod
Oct 20, 2020 9:42am
BMS, Exelixis score a kidney cancer win. But can they nab share?
Apr 21, 2020 11:21am
NICE rejects Merck's Keytruda kidney cancer combo
Feb 12, 2020 11:29am
Pfizer nixes multiple Bavencio tests
Jan 28, 2020 11:55am